Inactivated or live-attenuated bivalent vaccines that confer protection against rabies and Ebola viruses

Joseph E. Blaney; Christoph Wirblich; Amy B. Papaneri; Reed F. Johnson; Carey J. Myers; Terry L. Juelich; Michael R. Holbrook; Alexander N. Freiberg; John G. Bernbaum; Peter B. Jahrling; Jason Paragas; Matthias J. Schnell

doi:10.1128/JVI.00558-11

Inactivated or live-attenuated bivalent vaccines that confer protection against rabies and Ebola viruses

Joseph E. Blaney, Christoph Wirblich, Amy B. Papaneri, Reed F. Johnson, Carey J. Myers, Terry L. Juelich, Michael R. Holbrook, Alexander N. Freiberg, John G. Bernbaum, Peter B. Jahrling, Jason Paragas, Matthias J. Schnell

Pathology

Research output: Contribution to journal › Article

56 Scopus citations

Abstract

The search for a safe and efficacious vaccine for Ebola virus continues, as no current vaccine candidate is nearing licensure. We have developed (i) replication-competent, (ii) replication-deficient, and (iii) chemically inactivated rabies virus (RABV) vaccines expressing Zaire Ebola virus (ZEBOV) glycoprotein (GP) by a reverse genetics system based on the SAD B19 RABV wildlife vaccine. ZEBOV GP is efficiently expressed by these vaccine candidates and is incorporated into virions. The vaccine candidates were avirulent after inoculation of adult mice, and viruses with a deletion in the RABV glycoprotein had greatly reduced neurovirulence after intracerebral inoculation in suckling mice. Immunization with live or inactivated RABV vaccines expressing ZEBOV GP induced humoral immunity against each virus and conferred protection from both lethal RABV and EBOV challenge in mice. The bivalent RABV/ZEBOV vaccines described here have several distinct advantages that may speed the development of inactivated vaccines for use in humans and potentially live or inactivated vaccines for use in nonhuman primates at risk of EBOV infection in endemic areas.

Original language	English (US)
Pages (from-to)	10605-10616
Number of pages	12
Journal	Journal of virology
Volume	85
Issue number	20
DOIs	https://doi.org/10.1128/JVI.00558-11
State	Published - Oct 1 2011

ASJC Scopus subject areas

Microbiology
Immunology
Insect Science
Virology

Access to Document

10.1128/JVI.00558-11

Fingerprint Dive into the research topics of 'Inactivated or live-attenuated bivalent vaccines that confer protection against rabies and Ebola viruses'. Together they form a unique fingerprint.

Cite this

Blaney, J. E., Wirblich, C., Papaneri, A. B., Johnson, R. F., Myers, C. J., Juelich, T. L., Holbrook, M. R., Freiberg, A. N., Bernbaum, J. G., Jahrling, P. B., Paragas, J., & Schnell, M. J. (2011). Inactivated or live-attenuated bivalent vaccines that confer protection against rabies and Ebola viruses. Journal of virology, 85(20), 10605-10616. https://doi.org/10.1128/JVI.00558-11

Inactivated or live-attenuated bivalent vaccines that confer protection against rabies and Ebola viruses. / Blaney, Joseph E.; Wirblich, Christoph; Papaneri, Amy B.; Johnson, Reed F.; Myers, Carey J.; Juelich, Terry L.; Holbrook, Michael R.; Freiberg, Alexander N.; Bernbaum, John G.; Jahrling, Peter B.; Paragas, Jason; Schnell, Matthias J.

In: Journal of virology, Vol. 85, No. 20, 01.10.2011, p. 10605-10616.

Research output: Contribution to journal › Article

Blaney, Joseph E. ; Wirblich, Christoph ; Papaneri, Amy B. ; Johnson, Reed F. ; Myers, Carey J. ; Juelich, Terry L. ; Holbrook, Michael R. ; Freiberg, Alexander N. ; Bernbaum, John G. ; Jahrling, Peter B. ; Paragas, Jason ; Schnell, Matthias J. / Inactivated or live-attenuated bivalent vaccines that confer protection against rabies and Ebola viruses. In: Journal of virology. 2011 ; Vol. 85, No. 20. pp. 10605-10616.

@article{caf0a1e79040491eb7161aa39dd590e8,

title = "Inactivated or live-attenuated bivalent vaccines that confer protection against rabies and Ebola viruses",

abstract = "The search for a safe and efficacious vaccine for Ebola virus continues, as no current vaccine candidate is nearing licensure. We have developed (i) replication-competent, (ii) replication-deficient, and (iii) chemically inactivated rabies virus (RABV) vaccines expressing Zaire Ebola virus (ZEBOV) glycoprotein (GP) by a reverse genetics system based on the SAD B19 RABV wildlife vaccine. ZEBOV GP is efficiently expressed by these vaccine candidates and is incorporated into virions. The vaccine candidates were avirulent after inoculation of adult mice, and viruses with a deletion in the RABV glycoprotein had greatly reduced neurovirulence after intracerebral inoculation in suckling mice. Immunization with live or inactivated RABV vaccines expressing ZEBOV GP induced humoral immunity against each virus and conferred protection from both lethal RABV and EBOV challenge in mice. The bivalent RABV/ZEBOV vaccines described here have several distinct advantages that may speed the development of inactivated vaccines for use in humans and potentially live or inactivated vaccines for use in nonhuman primates at risk of EBOV infection in endemic areas.",

author = "Blaney, {Joseph E.} and Christoph Wirblich and Papaneri, {Amy B.} and Johnson, {Reed F.} and Myers, {Carey J.} and Juelich, {Terry L.} and Holbrook, {Michael R.} and Freiberg, {Alexander N.} and Bernbaum, {John G.} and Jahrling, {Peter B.} and Jason Paragas and Schnell, {Matthias J.}",

year = "2011",

month = oct,

day = "1",

doi = "10.1128/JVI.00558-11",

language = "English (US)",

volume = "85",

pages = "10605--10616",

journal = "Journal of Virology",

issn = "0022-538X",

publisher = "American Society for Microbiology",

number = "20",

}

TY - JOUR

T1 - Inactivated or live-attenuated bivalent vaccines that confer protection against rabies and Ebola viruses

AU - Blaney, Joseph E.

AU - Wirblich, Christoph

AU - Papaneri, Amy B.

AU - Johnson, Reed F.

AU - Myers, Carey J.

AU - Juelich, Terry L.

AU - Holbrook, Michael R.

AU - Freiberg, Alexander N.

AU - Bernbaum, John G.

AU - Jahrling, Peter B.

AU - Paragas, Jason

AU - Schnell, Matthias J.

PY - 2011/10/1

Y1 - 2011/10/1

N2 - The search for a safe and efficacious vaccine for Ebola virus continues, as no current vaccine candidate is nearing licensure. We have developed (i) replication-competent, (ii) replication-deficient, and (iii) chemically inactivated rabies virus (RABV) vaccines expressing Zaire Ebola virus (ZEBOV) glycoprotein (GP) by a reverse genetics system based on the SAD B19 RABV wildlife vaccine. ZEBOV GP is efficiently expressed by these vaccine candidates and is incorporated into virions. The vaccine candidates were avirulent after inoculation of adult mice, and viruses with a deletion in the RABV glycoprotein had greatly reduced neurovirulence after intracerebral inoculation in suckling mice. Immunization with live or inactivated RABV vaccines expressing ZEBOV GP induced humoral immunity against each virus and conferred protection from both lethal RABV and EBOV challenge in mice. The bivalent RABV/ZEBOV vaccines described here have several distinct advantages that may speed the development of inactivated vaccines for use in humans and potentially live or inactivated vaccines for use in nonhuman primates at risk of EBOV infection in endemic areas.

AB - The search for a safe and efficacious vaccine for Ebola virus continues, as no current vaccine candidate is nearing licensure. We have developed (i) replication-competent, (ii) replication-deficient, and (iii) chemically inactivated rabies virus (RABV) vaccines expressing Zaire Ebola virus (ZEBOV) glycoprotein (GP) by a reverse genetics system based on the SAD B19 RABV wildlife vaccine. ZEBOV GP is efficiently expressed by these vaccine candidates and is incorporated into virions. The vaccine candidates were avirulent after inoculation of adult mice, and viruses with a deletion in the RABV glycoprotein had greatly reduced neurovirulence after intracerebral inoculation in suckling mice. Immunization with live or inactivated RABV vaccines expressing ZEBOV GP induced humoral immunity against each virus and conferred protection from both lethal RABV and EBOV challenge in mice. The bivalent RABV/ZEBOV vaccines described here have several distinct advantages that may speed the development of inactivated vaccines for use in humans and potentially live or inactivated vaccines for use in nonhuman primates at risk of EBOV infection in endemic areas.

UR - http://www.scopus.com/inward/record.url?scp=80055058700&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80055058700&partnerID=8YFLogxK

U2 - 10.1128/JVI.00558-11

DO - 10.1128/JVI.00558-11

M3 - Article

C2 - 21849459

AN - SCOPUS:80055058700

VL - 85

SP - 10605

EP - 10616

JO - Journal of Virology

JF - Journal of Virology

SN - 0022-538X

IS - 20

ER -